Toll-like Receptor 9 Promotes Initiation of Gastric Tumorigenesis by Augmenting Inflammation and Cellular Proliferation

Ke Tang,1,2 Louise McLeod,1,2 Thaleia Livis,1,2 Alison C. West,1,2 Ruby Dawson,1,2 Liang Yu,1,2 Jesse J. Balic,1,2 Michelle Chonwerawong,1,2 Georgie Wray-McCann,1,2 Hiroko Oshima,3 Masanobu Oshima,3 Virginie Deswaerte,1,2 Richard L. Ferrero,1,2,4 and Brendan J. Jenkins1,2

1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia; 2Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia; 3Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; and 4Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia

SUMMARY
We reveal that the innate immune toll-like receptor 9 (TLR9) promotes the initiating stages of gastric carcinogenesis, including that triggered by Helicobacter pylori infection. These findings provide in vivo evidence for TLR9 as a candidate therapeutic target in gastric cancer.

BACKGROUND & AIMS: Gastric cancer (GC) is strongly linked with chronic gastritis after Helicobacter pylori infection. Toll-like receptors (TLRs) are key innate immune pathogenic sensors that mediate chronic inflammatory and oncogenic responses. Here, we investigated the role of TLR9 in the pathogenesis of GC, including Helicobacter infection.

METHODS: TLR9 gene expression was profiled in gastric tissues from GC and gastritis patients and from the spontaneous gp130+/− GC mouse model and chronic H felis-infected wild-type (WT) mice. Gastric pathology was compared in gp130+/− and H felis infection models with or without genetic ablation of Tlr9. The impact of Tlr9 targeting on signaling cascades implicated in inflammation and tumorigenesis (eg, nuclear factor kappa B, extracellular signal-related kinase, and mitogen-activated protein kinase) was assessed in vivo. A direct growth-potentiating effect of TLR9 ligand stimulation on human GC cell lines and gp130+/− primary gastric epithelial cells was also evaluated.

RESULTS: TLR9 expression was up-regulated in Helicobacter-infected gastric tissues from GC and gastritis patients and gp130+/− and H felis-infected WT mice. Tlr9 ablation suppressed initiation of tumorigenesis in gp130+/−/Tlr9−/− mice by abrogating gastric inflammation and cellular proliferation. Tlr9−/− mice were also protected against H felis-induced gastric inflammation and hyperplasia. The suppressed gastric pathology upon Tlr9 ablation in both mouse models associated with attenuated nuclear factor kappa B and, to a lesser extent, extracellular signal-related kinase, mitogen-activated protein kinase signaling. TLR9 ligand stimulation of human GC cells and gp130+/− GECs augmented their proliferation and viability.

CONCLUSIONS: Our data reveal that TLR9 promotes the initiating stages of GC and facilitates Helicobacter-induced gastric inflammation and hyperplasia, thus providing in vivo evidence for TLR9 as a candidate therapeutic target in GC. (Cell Mol Gastroenterol Hepatol 2022;□□–□□; https://doi.org/10.1016/j.jcmgh.2022.06.002)

Keywords: Gastric Cancer; Initiation; H pylori; TLR9.

Gastric cancer (GC) is the third most lethal cancer worldwide, with 5-year relative survival rates lower than 25% because of the late diagnosis and limited effectiveness of current treatments.1,2 The major histopathologic type of human GC is intestinal-type adenocarcinoma, which develops stepwise from superficial gastritis (ie, gastric inflammation), atrophic gastritis, intestinal metaplasia, and dysplasia.3 GC is also divided into cardia and non-cardia topographical subsites in the stomach, the latter of which has a higher frequency and is associated with infection by Helicobacter pylori, a Gram-negative bacterial pathogen that accounts for ~6% of the global cancer burden.1,5

The strong association between H pylori-induced gastritis and GC implicates host immune regulators with pro-tumorigenic activities, albeit currently ill-defined, in promoting the molecular pathogenesis of GC. In this respect, H pylori exerts its pathogenicity through interactions with the host mucosal immune system, in which innate immune toll-like receptors (TLRs) play a vital role in recognizing diverse ligands of microbial and host origins to orchestrate the ensuing inflammatory response.5,7 Over recent years, it has emerged that TLRs may also contribute to the pathogenesis of human malignancies, including GC, via the regulation of epithelial cell proliferation, apoptosis, and cancer stem cell properties.

Abbreviations used in this paper: ANOVA, analysis of variance; ERK, extracellular signal-related kinase; GC, gastric cancer; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa B; PCNA, proliferating cell nuclear antigen; PI3K, phosphatidylinositol-3-kinase; qPCR, quantitative polymerase chain reaction; TCGA, The Cancer Genome Atlas; TLR, toll-like receptor; TME, tumor microenvironment; WT, wild-type.

© 2022 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 2362-348X
https://doi.org/10.1016/j.jcmgh.2022.06.002
epithelial-mesenchymal transition, angiogenesis, metastasis, and immunosuppression through multiple signaling pathways. These oncogenic TLR-driven reponses are transduced via numerous signaling cascades, such as nuclear factor kappa B (NF-kB), extracellular signal-related kinase (ERK) mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K)/Akt. Among TLR family members, clinical studies have shown often contrasting correlations between increased GC risk and single nucleotide polymorphisms in TLR2, TLR4, TLR5, and TLR9. This is most likely explained by the high degree of genetic and molecular heterogeneity in human GC, together with study design differences based on patient characteristics (eg, geographical location, ethnicity, age, tumor stage, histologic grade, anatomic location). With respect to TLR2, its up-regulated expression in tumors from GC patients is associated with poor survival outcomes, and using the gp130+/− spontaneous mouse model for intestinal-type GC, along with human GC xenografts, we have demonstrated that the up-regulation of TLR2 in gastric epithelial (tumor) cells promotes tumorigenesis in a tumor cell intrinsic manner (ie, independent of tumor inflammation). Despite these observations, a causal role for other TLRs in the molecular pathogenesis of GC remains ill-defined.

TLR9 is an endosomal sensor of unmethylated CpG-rich DNA motifs and is up-regulated in numerous human cancers affecting the lung, pancreas, breast, esophagus, nasopharynx, and brain, as well as in H pylori-positive GC. Numerous in vitro and in vivo studies have shown that TLR9 promotes distinct pro-tumorigenic effects in immune and non-immune cells, including angiogenesis, immunosuppression, cell proliferation, and invasion. Conversely, TLR9 agonists can also trigger anti-tumor immunity in some cancer types (eg, lung, colon). Indeed, the complex and contrasting contribution of TLR9 signaling to carcinogenesis also extends to gastric inflammation in vivo models induced by Helicobacter infection (3–6 weeks), whereby acute host immune responses are either suppressed (neutrophil infiltrates, interferon γ production) or augmented (interleukin 17 production) in infected Tlr9−/− mice.

To provide definitive insights into the mechanistic role of TLR9 in inflammation-associated GC, here we show that TLR9 expression was elevated in both uninfected gp130+/− and chronic (4-month) Helicobacter-infected wild-type (WT) mice, as well as in clinical biopsies from GC and H pylori-infected gastritis patients. Furthermore, by coupling Tlr9−/− mice with uninfected gp130+/− mice, we reveal that the genetic ablation of Tlr9 suppressed the onset of gastric tumorigenesis, which was accompanied by reduced gastric mucosal inflammation and cellular proliferation. Similarly, H felis-induced gastric inflammation and epithelial hyperplasia were ameliorated in Tlr9−/− mice. Collectively, our findings demonstrate that activation of TLR9 signaling promotes gastric tumorigenesis in the initiating stage, at least in part, by augmenting inflammation and cellular proliferation.

**Results**

**TLR9 Expression Is Augmented in Early-Stage Gastric Tumors of Gastric Cancer Patients and Correlates With Impaired Survival**

In 2 independent GC patient cohorts, The Cancer Genome Atlas (TCGA) and an Australian-based mixed Caucasian/Asian cohort, TLR9 mRNA levels were significantly up-regulated in 78% (14/18) and 65% (13/20) of gastric tumor tissues, respectively, compared with matched adjacent non-tumor tissues (Figure 1A–D, Table 1). Among all TLR family members, only TLR9 along with TLR2 were significantly up-regulated in gastric tumor tissues from GC patients; the latter observation for TLR2 is consistent with our previous report8,10 (Figure 1A). Interestingly, in the large GCaP Project ‘08 – Singapore Patient Cohort comprising tumor only samples (Table 1), the segregation of GC patient primary tumors into either low or high TLR9 gene expression revealed that high TLR9 levels were prognostic for impaired overall >10-year survival, with patients expressing high versus low TLR9 mRNA levels having a median survival of 31.2 versus 56.9 months (Figure 1E). We also note that the stratification of GC patients by disease stage showed that among TLRs, only TLR9 mRNA expression levels were significantly elevated in early-stage I and II patients compared with advanced-stage III and IV patients (Figure 1F). Collectively, these data indicate that augmented TLR9 expression is a feature of early-stage human GC.

**Genetic Targeting of TLR9 in the gp130+/− Gastric Cancer Mouse Model Suppresses Tumor Initiation, but not Progression**

We next assessed the expression of Tlr9 by quantitative polymerase chain reaction (qPCR) in the preclinical gp130+/−/C138 JCMGH1031 gastric cancer mouse model, which from 6 weeks of age onward spontaneously develops antral gastric intestinal-type tumors (with 100% penetrance) that progress in size until a maximal growth is reached at 24–26 weeks of age. Although gastric Tlr9 mRNA levels were unchanged in pre-tumorigenic 4-week-old gp130+/− mice, Tlr9 gene expression was significantly elevated (2- to 3-fold) at 12 weeks of age in gp130+/− gastric antral tumors compared with either adjacent non-tumor antral tissue or normal antral tissues of gp130−/− (WT) mice (Figure 2A). Notably, laser microdissection coupled with qPCR on gastric tissues from tumor-bearing gp130+/− versus tumor-free WT mice indicated that Tlr9 mRNA levels were elevated in the epithelium (enriched for Epcam gene expression) versus immune cell-containing stroma (enriched for Ptprc (CD45) gene expression) within each gastric tissue genotype, with highest Tlr9 gene expression observed in the gp130+/− tumor epithelium (Figure 2B). In support of these observations, Tlr9 mRNA levels were also significantly higher in primary gastric epithelial cells derived from gp130+/− versus WT mice (Figure 2C). Conversely, at 24 weeks of age Tlr9 mRNA levels were significantly elevated (2- to 3-fold) in gp130+/− non-tumor antral tissue compared with both.
$gp130^{F/F}$ gastric antral tumors and WT antral tissues (Figure 2A).

To define whether a causal relationship exists between increased gastric tumoral expression of TLR9 and the pathogenesis of GC, we generated TLR9-deficient $gp130^{F/F}$ mice ($gp130^{F/F};Tlr9^{/-}$). By 10 weeks of age (early-stage tumorigenesis), the stomachs and gastric tumors of $gp130^{F/F};Tlr9^{/-}$ mice were visibly smaller and significantly
reduced in weight (49% and 62%, respectively) compared with age-matched gp130\(^{-/}\) littermates (Figure 2D–F). Surprisingly, however, suppressed gastric tumorigenesis was not apparent in 20-week-old and 30-week-old gp130\(^{-/}\):Tlr9\(^{-/-}\) mice, in which both stomach size and gastric tumor burden were comparable with age-matched gp130\(^{-/}\) mice (Figure 2G–L). We note that tumor incidence was similar between the genotypes at each age group (Figure 2M). Therefore, genetic ablation of TLR9 in the gp130\(^{-/}\) GC model preferentially inhibits the early initiation, but not later establishment and progression, stage of gastric tumorigenesis.

### Suppressed Early-Stage Gastric Tumorigenesis in gp130\(^{-/-}\):Tlr9\(^{-/-}\) Mice Is Associated With Reduced Gastric Inflammation and Cellular Proliferation

We next evaluated whether the suppressed early GC phenotype of gp130\(^{+/}\):Tlr9\(^{-/-}\) mice coincided with reduced tumor-associated inflammation. Indeed, histologic assessment of H&E-stained gastric tissue sections from 10-week-old mice indicated that the inflammation score (chronic inflammatory cell infiltrates in the submucosa and mucosa) in gp130\(^{+/}\),Tlr9\(^{-/-}\) gastric tumors was significantly lower compared with age-matched gp130\(^{+/}\) tumors (Figure 3A). Immunohistochemical analyses also indicated significantly lower numbers of infiltrating CD45\(^{+}\) leukocytes, B220\(^{+}\) B cells, and CD3\(^{+}\) T cells in the gastric mucosa of 10-week-old gp130\(^{+/}\),Tlr9\(^{-/-}\) versus gp130\(^{+/}\) mice (Figure 3B–D). The reduced gastric inflammation in smaller gp130\(^{+/}\),Tlr9\(^{-/-}\) tumors was also confirmed at the molecular level, as evidenced by significantly lower mRNA levels of inflammatory genes (Tnfa, Cxcl1, Cxcl2) and protein levels of tumor necrosis factor \(\alpha\) in 10-week-old gp130\(^{+/}\),Tlr9\(^{-/-}\) versus gp130\(^{+/}\) gastric tumors (Figure 3E and F). By contrast, the expression of several angiogenesis-related genes (Mmp2, Mmp9, Vegf) was comparable in gastric tumors of gp130\(^{+/}\),Tlr9\(^{-/-}\) and gp130\(^{+/}\) mice, suggesting that TLR9 does not promote angiogenesis in the early stages of tumor growth.
establishment stage of gastric tumorigenesis (Figure 3G).

Consistent with the comparable gastric tumorigenesis in older (20-week-old) gp130fi/-;Tlr9fi/- and gp130fl/+ mice,
similar levels of gastric inflammation were observed in tu-
mors of aged gp130fi/-;Tlr9fi/- and gp130fl/+ mice
(Figure 3H–K). We also note a previous report that aberrant
activation of M2-type macrophages can be associated with
gastric tumor growth in mice.49 Consistent with this, we
observed transcriptional up-regulation of M2-type markers
(Arg1, Egr2), but not M1-type markers (Cd38, Gpr18), in
gp130fi/+ gastric tumors (Figure 3L). However, TLR9 defi-
ciency in gp130fi/-;Tlr9fi/- mice did not alter the gastric
expression profile of these M2-type macrophage markers,
suggesting TLR9 promotes gastric inflammation and
tumorigenesis independent of M2-type macrophage activa-
tion (Figure 3L).

Because elevated gastric epithelial cell proliferation and
survival are prominent features of early-stage gastric
tumorigenesis in gp130fl/+ mice,8,25 we next investigated
whether TLR9 promoted these oncogenic cellular processes
in 10-week-old gp130fl/+ mice. Indeed, immunohistochem-
istry indicated that proliferating cell nuclear antigen
(PCNA) proliferating cell numbers were signifi-
cantly decreased (~40%) in the epithelium of gastric tumors of
gp130fi/-;Tlr9fi/- compared with gp130fl/+ mice (Figure 4A).
These observations were also supported at the molecular
level, whereby the expression of a series of proliferative
markers (Bcl2a1, Ccnb1, Ccnd1, Myc) was significantly
reduced in gastric tumors from 10-week-old gp130fl/+;Tlr9fi/- mice
compared with their age-matched gp130fl/+ control mice
(Figure 4B). By contrast, with respect to cell survival,
apoptotic cleaved Caspase-3+ or TUNEL+ cell numbers in
10-week-old gp130fl/+;Tlr9fi/- and gp130fl/+ gastric tumors were
comparable (Figure 4C and D). Notably, similar levels of
cellular proliferation and apoptosis and proliferative gene
expression were observed in tumors of aged (20-week-old)
gp130fl/+;Tlr9fi/- and gp130fl/+ mice (Figure 4E–G). Collect-
ively, these data indicate that TLR9 selectively promotes
cellular proliferation and inflammation during the early
establishment of gastric tumors in the gp130fl/+ GC mouse
model.

Suppressed Early-Stage Gastric Tumorigenesis
in gp130fl/+;Tlr9fi/- Mice Is Associated With
Reduced Activation of Nuclear Factor Kappa B
and Extracellular Signal-Related Kinase Mitogen-
Activated Protein Kinase Signaling Cascades

To identify TLR9-dependent signaling pathways associ-
ated with early-stage gastric tumorigenesis in 10-week-old
gp130fl/+ mice, we performed Western blots to evaluate the
activation (phosphorylation) of NF-κB, ERK1/2, MAPK,
PI3K/Akt, and STAT3 pathways. The protein levels of
phosphorylated (p) NF-κB p65 and pERK1/2 were signifi-
cantly lower (42% and 20%, respectively) in gastric tumor
lysates of 10-week-old gp130fl/+;Tlr9fi/- compared with
gp130fl/+ mice, whereas levels of pAkt and pSTAT3 were
comparable between these 2 genotypes (Figure 5A–D). We
further verified that reduced tumorigenesis in gp130fl/+;Tlr9fi/- mice was not a consequence of altered
STAT3 signaling, as evidenced by comparable mRNA
expression levels of STAT3-target genes (Socs3, Il11) in tu-
mors of 10-week-old gp130fl/+;Tlr9fi/- and gp130fl/+ mice
(Figure 5E). Immunohistochemical analyses also confirmed
dehiscence of pNF-κB p65+ and pERK1/2+ cell numbers in
gastric tumors, predominantly the glandular epithelium, of
10-week-old gp130fl/+;Tlr9fi/- versus gp130fl/+ mice, with the
reduction again more pronounced for pNF-κB p65+ (45%) than pERK1/2+ (30%) (Figure 5F and G). By contrast, at 20
weeks of age, expression levels of pNF-κB p65+ (very low)
and pERK1/2+ were comparable in tumors between
gp130fl/+;Tlr9fi/- versus gp130fl/+ mice (Figure 5H and I),
suggesting that TLR9 does not engage these pathways in
later stages of tumorigenesis. Taken together, these data
support the notion that genetic targeting of TLR9 inhibits
early-stage gastric tumorigenesis in 10-week-old gp130fl/+.
**TLR9 Initiates Gastric Tumorigenesis**

**Figure A:** H&E staining of stomach sections from F/F and F/F: Tlr9^-/- groups. Inflammation score for CD45+ cells.

**Figure B:** CD45+ cells/HPF for F/F and F/F: Tlr9^-/- groups.

**Figure C:** B220+ cells/HPF for F/F and F/F: Tlr9^-/- groups.

**Figure D:** CD3+ cells/HPF for F/F and F/F: Tlr9^-/- groups.

**Figure E:** Relative expression of Cxcl1, Cxcl2, and Tnfa.

**Figure F:** TNFα pg/mg tissue lysate for F/F and F/F: Tlr9^-/- groups.

**Figure G:** Relative expression of Mmp2, Mmp9, and Vegf.

**Figure H:** H&E staining of stomach sections from WT and F/F groups. Inflammation score for CD45+ cells.

**Figure I:** CD45+ cells/HPF for WT and F/F: Tlr9^-/- groups.

**Figure J:** B220+ cells/HPF for WT and F/F: Tlr9^-/- groups.

**Figure K:** CD3+ cells/HPF for WT and F/F: Tlr9^-/- groups.

**Figure L:** Relative expression of Cd38, Gpr18, Arg1, and Egr2 for WT, F/F, and F/F: Tlr9^-/- groups.
Increased TLR9 Expression in Human and Mouse Gastric Epithelial (Cancer) Cells Enhances TLR9 Ligand-Driven Cell Growth

Because of the recent emergence that TLR family members (ie, TLR2) can exert pro-tumorigenic effects by directly acting on GC cells to augment their cellular proliferation and survival,7,8,12,13 we investigated whether ligand-induced activation of TLR9 could directly enhance the growth responsiveness of human GC cell lines. For this purpose, we used qPCR and Western blotting to stratify a panel of 9 human GC cell lines, along with a control human duodenal cancer cell line (AZ521), into either TLR9 low-expressing (TLR9low) (N87, SNU16, TMK1, AGS, MKN7) and TLR9 high-expressing (TLR9high) (SNU601, MKN1, MKN28, NUGC4) cell lines (Figure 6A–C, Table 2). We next stimulates representative TLR9high NUGC4 and MKN28 cell lines, along the TLR9low AGS cell line as a control, with the TLR9 agonist CpG DNA to measure cell proliferation and cell viability. As shown in Figure 6D and E, both cellular proliferation and viability of TLR9high NUGC4 and MKN28 cell lines were significantly enhanced on TLR9 ligand stimulation, whereas TLR9low AGS cells were non-responsive. The capacity of TLR9 activation to augment the proliferation of gastric epithelial cancer cells was also confirmed in TLR9 high-expressing primary gastric epithelial cells from the gp130F/F GC mouse model, with CpG DNA-stimulated gp130F/F epithelial cell cultures displaying a significant increase in proliferation compared with control-treated cultures (Figure 6F–H).

Our in vivo data in the gp130F/F model suggest that TLR9 activates NF-κB and, to a lesser extent, ERK MAPK pathways to promote cellular proliferation within the gastric epithelium during tumorigenesis. To further delineate a role for these pathways in transducing TLR9-induced proliferation and viability of gastric epithelial (cancer) cells, we pre-treated NUGC4 and MKN28 human GC cells with well-documented inhibitors of the NF-κB (TPCA-1; 1κB kinase-2 inhibitor) and ERK1/2 MAPK (U0126; MAPK kinase inhibitor) pathways before stimulation with CpG DNA. As shown in Figure 6f, treatment with TPCA-1, but not U0126, resulted in a significant inhibition of TLR9 ligand-stimulated cell proliferation and viability. Taken together, these in vitro data demonstrating enhanced TLR9-driven cellular growth are coincident with our in vivo findings in the gp130F/F model that TLR9 promotes tumor (epithelial) cell proliferation predominantly via the NF-κB pathway.

Up-Regulation of TLR9 During Helicobacter Infection Exacerbates Gastric Hyperplasia and Inflammation in Vivo

Because H pylori infection triggers the initiating pre-neoplastic, chronic gastritis stage of GC,2,3 we next investigated the pathologic role of TLR9 in Helicobacter-induced gastric disease. TLR9 gene expression profiling of gastric tumors from GC patients stratified for their H pylori status revealed that TLR9 mRNA levels were significantly higher (~1.5- to 2-fold) in H pylori-positive patients (TCGA and Australian/Chinese cohorts) compared with the corresponding H pylori-negative patients (Figure 7A and B). Similarly, in GC-free individuals, TLR9 gene expression was elevated (~4-fold) in H pylori-positive versus H pylori-negative gastric tissues (Figure 7C). Notably, TLR9 expression in H pylori-negative gastric tissues was unchanged irrespective of the grade of gastritis (Figure 7C), suggesting that increased TLR9 expression in GC-free gastric tissues was specifically associated with H pylori infection.

H felis strongly colonizes the mouse stomach and induces inflamed, hyperplastic gastric lesions that are similar in pathology to the pre-neoplastic, inflammatory lesions triggered by H pylori infection in the human stomach.20 We therefore established a chronic H felis infection model in WT mice, which was characterized by significant increases in stomach weight and gastric corpus mucosal thickness, as well as upregulation (~3-fold) of Tnf mRNA levels in the gastric body at 4 months after infection, compared with broth control gavaged mice (Figure 7D–G). Notably, H felis-infected Tlr9–/– mice displayed markedly reduced stomach size and weight (32%) and gastric corpus mucosal thickness (25%), compared with H felis-infected WT mice (Figure 7E–G). Western blot analyses on gastric tissue lysates from H felis-infected mice, at least in part, through suppressed activation of NF-κB and ERK pathways, but not via PI3K/Akt or STAT3 pathways.
Figure 4. TLR9 promotes cellular proliferation, but not survival, in tumors of 10-week-old gp130^F/F mice. (A, C, and D) Representative photomicrographs showing (A) PCNA-stained, (C) cleaved Caspase-3-stained, and (D) TUNEL-stained cross sections under low power (left images) and high power (right images) magnification in gastric tumors from 10-week-old (wo) gp130^F/F (F/F) and F/F:Tlr9^+/− mice. Scale bars: 100 μm (left images), 25 μm (right images). In (D), arrows point to representative TUNEL-positive stained cells. Also shown are the corresponding graphs depicting quantification of positive cells/high-power field (HPF), n = 6 mice/genotype. ***P < .001; unpaired Student t tests. (B) qPCR of the indicated cell proliferation genes (all relative to 18s rRNA) in gastric tumors from 10wo F/F and F/F:Tlr9^+/− mice. n = 6 mice/genotype. *P < .05; unpaired Student t tests. (E and F) Representative photomicrographs of (E) PCNA-stained and (F) TUNEL-stained cross sections under low power (left images) and high power (right images) magnification of gastric tumors from 20wo F/F and F/F:Tlr9^+/− mice. Scale bars: 100 μm (left images), 25 μm (right images). In (F), arrows point to representative TUNEL-positive stained cells Also shown are corresponding graphs depicting positive cells/HPF, n = 6 mice/genotype. (G) qPCR of the indicated cell proliferation genes (all relative to 18s rRNA) in gastric tumors from 20wo F/F and F/F:Tlr9^+/− mice. n = 6 mice/genotype.
Figure 5. TLR9 promotes gastric tumorigenesis in 10-week-old gp130<sup>F/F</sup> mice through multiple signaling cascades. (A–D) Western blots of gastric tumor tissue lysates from 10-week-old (wo) gp130<sup>F/F</sup> (F/F) and F/F: Tlr9<sup>−/−</sup> mice with the indicated antibodies. Each lane represents an individual mouse sample. Graphs depict densitometric quantification of relative expression of phosphorylated signaling molecules (ratio of phosphorylated versus total protein) from the corresponding blots on gastric tumor tissue lysates (n = 6 mice/genotype). (E) qPCR of the indicated genes (relative to 18s rRNA) in gastric tumors from 10wo F/F and F/F: Tlr9<sup>−/−</sup> mice. (F and G) Representative high power photomicrographs showing immunohistochemical staining of (F) pNF-κB p65 and (G) pERK1/2 in cross sections of gastric tumors from 10wo F/F and F/F: Tlr9<sup>−/−</sup> mice. Scale bars: 50 μm. Graphs depict the corresponding enumeration of positive cells/high power field (HPF). n = 6 mice/genotype. *P < .05, **P < .01; unpaired Student t test. (H) Western blots of gastric tumor tissue lysates from 20wo F/F and F/F: Tlr9<sup>−/−</sup> mice with the indicated antibodies. Each lane represents an individual mouse sample. (I) Graphs depict densitometric quantification of the relative expression of phosphorylated signaling molecules (ratio of phosphorylated versus total protein) from the corresponding blots on gastric tumor tissue lysates (n = 5 mice/genotype).

and broth gavaged WT and Tlr9<sup>−/−</sup> mice showed that protein levels of pNF-κB p65 and pERK1/2 MAPK were significantly higher in the gastric mucosa of H. felis-infected WT mice than H. felis-infected Tlr9<sup>−/−</sup> mice, the latter of which were similar to WT and Tlr9<sup>−/−</sup> broth control animals (Figure 7H). Therefore, these data suggest that TLR9-dependent NF-κB and ERK1/2 MAPK signaling pathways contribute to H. felis-induced gastric pathogenesis in vivo.
Figure 6. TLR9 promotes human GC and mouse gp130\(^{+/−}\) primary gastric epithelial cell growth in vitro. (A) qPCR expression analyses of TLR9 (normalized to the housekeeping gene ACTB) in human GC cell lines (black bars) and a control duodenal cancer cell line (white bar). Expression values were relative to AGS (assigned a value of “1”), and cell lines with a relative expression value above 1 were defined as high expressing for TLR9, as depicted by the dotted line. (B) Western blots of lysates from human GC cell lines with the indicated antibodies. (C) Densitometry quantification of TLR9 protein expression from (B) relative to tubulin. (D and E) Cell proliferation (D) and viability (E) assays of AGS (TLR9\(^{−/−}\)), NUGC4 (TLR9\(^{High}\)), and MKN28 (TLR9\(^{High}\)) cells treated with either TLR9 ligand CpG-DNA (ODN-2006) (2 \(\mu\)mol/L) or control oligonucleotide for 24 and 48 hours, respectively. Data are presented from 3 independent experiments. *\(P < .05\); paired Student t test. (F and G) Representative immunofluorescence images of (F) gp130\(^{+/−}\) (F/F) primary gastric epithelial cells (GECs) stained for E-cadherin and (G) WT and F/F primary GECs stained for TLR9. DAPI nuclear staining is blue. Scale bars: 50 \(\mu\)m. (H) Proliferation assays of F/F primary GECs treated with either TLR9 ligand CpG-DNA (ODN-2006) (2 \(\mu\)mol/L) or control oligonucleotide for 24 hours. Data are presented from 3 independent experiments. *\(P < .05\); paired Student t test. (I) Cell proliferation and viability assays of NUGC4 cells pretreated with inhibitors of the NF-\(\kappa\)B (TPCA-1) and ERK1/2 MAPK (U0126) pathways before stimulation with CpG DNA (2 \(\mu\)mol/L) or control oligonucleotide for 24 and 48 hours, respectively. Data are presented from 3 independent experiments. *\(P < .05\), ***\(P < .001\), ****\(P < .0001\); one-way ANOVA.
Table 2. Significance Values Were Calculated for TLR9 Gene Expression (by qPCR) Among TLR9HIGH (SNU601, MKN1, MKN28, NUGC4) and TLR9LOW (N87, SNU16, TMK1, AGS, MKN7) Human Gastric Cancer and Duodenal (AZ521; TLR9LOW) Cell Lines

<table>
<thead>
<tr>
<th>Cell line comparison</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZ521 vs SNU16</td>
<td>****</td>
</tr>
<tr>
<td>AZ521 vs AGS</td>
<td>****</td>
</tr>
<tr>
<td>AZ521 vs MKN7</td>
<td>****</td>
</tr>
<tr>
<td>AZ521 vs SNU601</td>
<td>****</td>
</tr>
<tr>
<td>AZ521 vs MKN1</td>
<td>****</td>
</tr>
<tr>
<td>AZ521 vs MKN28</td>
<td>****</td>
</tr>
<tr>
<td>AZ521 vs NUGC4</td>
<td>****</td>
</tr>
<tr>
<td>N87 vs SNU16</td>
<td>***</td>
</tr>
<tr>
<td>N87 vs TMK1</td>
<td>*</td>
</tr>
<tr>
<td>N87 vs AGS</td>
<td>***</td>
</tr>
<tr>
<td>N87 vs MKN7</td>
<td>***</td>
</tr>
<tr>
<td>N87 vs SNU601</td>
<td>***</td>
</tr>
<tr>
<td>N87 vs MKN1</td>
<td>***</td>
</tr>
<tr>
<td>N87 vs MKN28</td>
<td>***</td>
</tr>
<tr>
<td>N87 vs NUGC4</td>
<td>***</td>
</tr>
<tr>
<td>SNU16 vs TMK1</td>
<td>***</td>
</tr>
<tr>
<td>SNU16 vs SNU601</td>
<td>***</td>
</tr>
<tr>
<td>SNU16 vs MKN1</td>
<td>***</td>
</tr>
<tr>
<td>SNU16 vs MKN28</td>
<td>***</td>
</tr>
<tr>
<td>SNU16 vs NUGC4</td>
<td>***</td>
</tr>
<tr>
<td>TMK1 vs AGS</td>
<td>***</td>
</tr>
<tr>
<td>TMK1 vs MKN7</td>
<td>***</td>
</tr>
<tr>
<td>TMK1 vs SNU601</td>
<td>***</td>
</tr>
<tr>
<td>TMK1 vs MKN1</td>
<td>***</td>
</tr>
<tr>
<td>TMK1 vs MKN28</td>
<td>***</td>
</tr>
<tr>
<td>TMK1 vs NUGC4</td>
<td>***</td>
</tr>
<tr>
<td>AGS vs SNU601</td>
<td>***</td>
</tr>
<tr>
<td>AGS vs MKN1</td>
<td>***</td>
</tr>
<tr>
<td>AGS vs MKN28</td>
<td>***</td>
</tr>
<tr>
<td>AGS vs NUGC4</td>
<td>***</td>
</tr>
<tr>
<td>MKN7 vs SNU601</td>
<td>***</td>
</tr>
<tr>
<td>MKN7 vs MKN1</td>
<td>***</td>
</tr>
<tr>
<td>MKN7 vs MKN28</td>
<td>***</td>
</tr>
<tr>
<td>MKN7 vs NUGC4</td>
<td>***</td>
</tr>
<tr>
<td>MKN7 vs MKN28</td>
<td>***</td>
</tr>
<tr>
<td>MKN7 vs NUGC4</td>
<td>***</td>
</tr>
</tbody>
</table>

*Analyses were performed using one-way ANOVA with Tukey multiple comparison test.

**P < .05, ***P < .001, ****P < .0001.

Assessment of gastric (antrum and corpus) mucosal cellular proliferation by PCNA and Ki67 immunohistochemical staining confirmed that the hyperproliferative gastric phenotype of WT mice on chronic *H. felis* infection was significantly attenuated by TLR9 deficiency (Figure 8A and B). These gastric parameters in *H. felis*-infected Tlr9−/− mice remained slightly higher than those in Tlr9+/− control animals, suggesting that TLR9 deficiency led to a partial (albeit significant) reduction in *H. felis*-induced gastric hyperplasia. These observations were also confirmed at the molecular level on qPCR gene expression analysis of markers for proliferative stem cells (*Lgr5*, *Cdx2*), chief cells (*Mist1*, *Bhila15*), parietal cells (*Atp4a*), and metaplasia (*Cd44v9*). Specifically, consistent with the suppressed gastric proliferative phenotype of *Helicobacter*-infected Tlr9−/− mice (versus WT mice), expression of *Lgr5* (increased during *Helicobacter* infection) was significantly down-regulated (~4.5-fold) in infected Tlr9−/− mice compared with WT mice (Figure 8C). With respect to metaplasia (which usually occurs subsequent to gastritis and associated hyperplasia) of chronic *Helicobacter* infection, gastric *Mist1* expression in chief cells, which is suppressed during metaplasia and dysplasia, was similarly down-regulated (5- to 6-fold) in both WT and Tlr9−/− mice infected with *Helicobacter* compared with their broth controls (Figure 8D). Also, *Cd44v9* mRNA levels (up-regulated on chronic *Helicobacter* infection and metaplasia) were similarly elevated (2- to 3-fold) in both WT and Tlr9−/− mice infected with *Helicobacter* compared with their broth controls (Figure 8E). Furthermore, consistent with the loss of parietal cells during *Helicobacter* infection and upon metaplasia, mRNA levels of *Atp4a* were similarly down-regulated (~4-fold) in WT and Tlr9−/− mice infected with *Helicobacter* compared with their broth controls (Figure 8F). Taken together, these molecular changes further support the notion that TLR9 contributes to early proliferative changes in the gastric mucosa, without impacting on lineage differentiation of gastric epithelial progenitors, during *Helicobacter* infection.

The reduced gastric hyperplasia in *H. felis*-infected Tlr9−/− mice was associated with lower gastric inflammation, as evidenced by significantly lower inflammation scores and reduced numbers of infiltrating CD45+, B220+, and CD3+ immune cell subsets in the stomachs of *H. felis*-infected Tlr9−/− mice compared with their infected WT counterparts (Figure 9A–D). Similarly, at the molecular level, elevated mRNA levels of inflammatory mediators (ie, *Ccl1*, *Ccl2*, *Tnfa*) in *H. felis*-infected WT mouse stomachs (compared with broth control WT) were also significantly lower in infected Tlr9−/− mouse stomachs (Figure 9E). Interestingly, the suppressed gastric inflammation (Figure 9A–D) and hyperplasia (Figure 8A and B) in infected Tlr9−/− mice occurred despite enhanced *H. felis* colonization (Figure 9F and G), which is consistent with the inverse relationship between *H. pylori* colonization and gastritis severity observed in the mouse stomach.34

**Discussion**

In this study, we reveal that the TLR9 endosomal DNA sensor promotes early-stage gastric inflammation-associated carcinogenesis. In this respect, our findings are consistent with accumulating evidence for the contribution of TLR9 to the pathogenesis of various cancers (eg, pancreatic cancer, esophageal cancer).13-17 For example, in...
Figure 7. TLR9 is up-regulated in human H pylori-infected and mouse H felis-infected gastric tissues, and H felis-induced gastric hyperplasia is suppressed in TLR9-deficient mice. (A and B) Gene expression of TLR9 in gastric tumors from (A) TCGA intestinal-type GC patients (Hp+, n = 53; Hp-, n = 4), and (B) Australian/Chinese GC patients (Hp+, n = 13; Hp-, n = 7), based on their H pylori (Hp) status. *P < .05; unpaired Student t test. (C) qPCR expression of TLR9 (relative to 18S rRNA) in gastric tissues from GC-free individuals, based on the H pylori status (Hp- normal (N), n = 8; Hp- mild gastritis (M), n = 12; Hp- severe gastritis (S), n = 8; total Hp+, n = 28; Hp+ severe gastritis (S), n = 11). **P < .01; one-way ANOVA. (D) qPCR expression of Tlr9 (relative to 18s rRNA) in gastric body tissues from WT mice at 4 months after oral gavage with either broth or H felis (Hf), n = 6 mice/group. **P < .01; unpaired Student t test. (E and F) Shown are (E) stomach weights and (F) mucosal thicknesses of WT and Tlr9-/- mice at 4 months after oral gavage with either broth or H felis (n = 12 mice/group). (G) Representative photomicrographs showing H&E-stained whole slide scans of stomachs. Scale bars: 1 mm. (H) Western blots of gastric body tissue lysates from Tlr9-/- and WT mice at 4 months after oral gavage with either broth or H felis with the indicated antibodies. Graphs depict densitometry quantification of the indicated phosphor-signaling molecules shown in the Western blots (n = 3 lysates/group), and relative expression was determined against the corresponding amount of total protein. *P < .05, **P < .01; one-way ANOVA.

pancreatic cancer, TLR9 has distinct pro-tumorigenic effects on epithelial, immune/inflammatory, and fibroblastic cells, which collectively fuel an inflamed tumor microenvironment (TME) during early disease onset that supports the neoplastic outgrowth of the transformed epithelium.13

Regarding the former, our findings here demonstrate that TLR9 elicits proliferative responses on the gastric epithelium during early-stage tumorigenesis, which is coincident with its transcriptional up-regulation in the gastric (tumor) epithelium, but not immune cell-containing stroma, of 12-week-old (early onset of tumorigenesis) versus 24-week-old (late established tumorigenesis) gp130F/F mice. These observations support the notion that in cancers (eg, pancreatic, gastric) whose initiation is reliant on tumor-promoting pro-inflammatory signals, TLR9-driven epithelial (tumor) cell growth, either directly or indirectly via activation of immune cells within the TME, outweights TLR9-mediated adaptive immune-based anti-tumor immunity that
has been described in certain cancer types (eg, brain, colon). The complex role of TLR9 in cancer is also evidenced by observations that TLR9 exhibits both tumor-promoting and tumor suppressive activities within a specific cancer type such as glioma. The mechanistic basis for these contrasting pro- and anti-tumorigenic effects of TLR9 remains unclear. However, it is likely to involve differences in the temporal (ie, early versus late stage) expression pattern of TLR9, as well as the cell types (eg, epithelial, immune) in which TLR9 is predominantly expressed, the latter of which is influenced by the highly heterogeneous TME among cancers.

The opposing roles of TLR9 in cancer also extend to contrasting observations on its pro- or anti-inflammatory activities in the pathogenesis of Helicobacter-induced gastritis. For instance, in a 3-week H felis infection mouse model, TLR9 elicited a pro-inflammatory response as evidenced by reduced numbers of infiltrating neutrophils in the gastric mucosa of infected Tlr9−/− mice. Importantly, our current study builds on this observation by demonstrating a causal role for TLR9 in promoting chronic H felis-induced gastric pathology, incorporating gastritis and gastric epithelial hyperplasia that are aligned with the initiating stages of H pylori-induced human GC. However, conversely, an anti-inflammatory role for TLR9 has been assigned during early phases of H pylori infection, whereby Tlr9−/− mice displayed elevated gastric neutrophil infiltration within 6–8 weeks after H pylori (SS1 and PMSS1 strains) infection. Although TLR9-mediated recognition of H pylori DNA is likely to be one mechanism by which Helicobacter species can hijack TLR9-dependent cellular responses in the host, the reason for the contrasting roles reported for TLR9 in Helicobacter-induced inflammatory responses is less clear but may involve differences in study design relating to the genetic backgrounds of mouse strains, variations within the gut microbiota observed among animal facilities, and/or strains of Helicobacter used (eg, H pylori SS1, H pylori PMSS1, H felis). It is also noteworthy to compare our findings on the role of TLR9 in promoting the early initiating stages of GC with those of other TLR family members, among which TLR2 is best characterized for its prominent role in driving the growth of established tumors in later stages of GC. A likely explanation for the differential roles of TLR2 and TLR9 in GC is that TLR2 drives tumorigenesis by directly augmenting proliferation and suppressing apoptosis of the
Figure 9. Genetic ablation of Tlr9 reduces H. felis-induced gastric inflammation. (A–D) Representative photomicrographs showing (A) H&E-stained, (B) CD45-stained, (C) B220-stained, and (D) CD3-stained cross-sections under low power (left images) and high power (right images) magnification through the body of stomachs from Tlr9−/− and WT mice at 4 months after oral gavage with either broth or H. felis. Also shown are the corresponding graphs depicting (A) the inflammation scores or (B–D) positive cells/high power field (HPF). Scale bars: 200 μm (left images) and 50 μm (right images). n = 6 mice/group. *P < .05, **P < .01, ****P < .0001; one-way ANOVA. (E) qPCR expression of representative inflammatory genes (relative to 18s rRNA) in gastric corpus (body) tissues from the stomachs of WT and Tlr9−/− mice at 4 months after oral gavage with either broth or H. felis. n = 6 mice/group. **P < .01, ***P < .001, ****P < .0001; one-way ANOVA. (F and G) In (F), qPCR expression of H. felis flaB (relative to Gapdh), and (G) representative agarose gel of reverse transcription PCR of H. felis flaB along with Gapdh, in stomachs from WT and Tlr9−/− mice at 4 months after oral gavage with either broth or H. felis. n = 6 mice/group. **P < .01, ***P < .001; one-way ANOVA.

transformed gastric epithelium, independent of its expression in immune cells (eg, bone marrow-driven myeloid lineage) and intratumoral inflammation.8,11 Furthermore, TLR2, unlike TLR9 (K.T. and B.J.J., unpublished data), is transcriptionally up-regulated in the transformed gastric epithelium by the latent oncogenic transcription factor STAT3, whose hyperactivation is a feature of >50% of human GC cases and drives tumorigenesis in the p161330F/F model, the latter of which mimics many of the molecular and cellular features of human GC, including that associated
with Helicobacter infection. Although the mechanism by which TLR9 is transcriptionally up-regulated in gastric inflammation-associated tumorigenesis is currently unknown, it is likely to involve NF-κB, whose dysregulated activation is a common feature of gastric tumorigenesis and Helicobacter infection. In addition, a single nucleotide polymorphism within the TLR9 promoter (TLR9-1237T/C), which increases TLR9 transcriptional activity in response to NF-κB, is associated with increased risk of H pylori-mediated premalignant changes in the gastric epithelium. These findings are in concordance with our current study, in which we observed elevated Thr9 mRNA levels in early, but not late, stage gp130F/F gastric tumors, which aligned with the high and very low levels of NF-κB activity in early and late stage gastric tumors, respectively.

In conclusion, our study defines a key role for TLR9 in the initiating stage of gastric inflammation-associated tumorigenesis (including that caused by Helicobacter infection), whereby up-regulation of TLR9 promotes the proliferative outgrowth of gastric epithelial cells. In the gp130F/F GC model, TLR9 deficiency led to the selective suppression of early initiation (10-week-old mice), but not later establishment and progression (20-week-old mice), stage of gastric tumorigenesis by transiently impairing the proliferative potential of the gastric epithelium, as well as immune cell infiltration in the TME. These observations aligned with reduced NF-κB (and to a lesser extent, ERK MAPK) activity on TLR9 deficiency in early (but not late) stage gp130F/F tumors, when TLR9 is also significantly up-regulated. Because activation of NF-κB (but not ERK MAPK) also associated with the TLR9-driven proliferative responsiveness of human GC cells, we propose that up-regulation of TLR9 in the gastric epithelium and concomitant preferential activation of NF-κB is an important step in the early stages of gastric tumorigenesis. Interestingly, because NF-κB is also a potent inducer of inflammatory responses, it is possible that TLR9 engages with NF-κB (and potentially other pathways) to also induce early inflammatory responses in the gastric compartment. We also note that in the later establishment and progression stages of gastric tumorigenesis, the chronic inflamed TME overrides the initial TLR9-driven activities on gastric epithelial and immune cells, thus promoting tumor progression independent of TLR9. In this regard, elevated Thr9 mRNA levels in the stroma-enriched non-tumor versus tumor tissues of 24-week-old gp130F/F mice are likely a consequence of the sustained presence of TLR9-expressing immune cell infiltrates in the highly inflamed gastric TME of 24-week-old gp130F/F mice. Moreover, our study raises the intriguing question of the relative contribution of TLR9 expression and activation in gastric epithelial versus immune cells to the pathogenesis of gastric inflammation and carcinogenesis. Although the host gastric epithelium is the first line of defense against H pylori, macrophages are critical facilitators of the early gastric inflammatory response to H pylori, whereby upon their recruitment to the infected gastric mucosa, they subsequently infected by H pylori, leading to their activation, which facilitates the recruitment and activation of additional inflammatory cells (eg, macrophages themselves, neutrophils, dendritic cells). Indeed, our observation that TLR9 is expressed in both gastric epithelial and immune cell-enriched stroma compartments, albeit at markedly reduced levels in the latter, supports the notion that although the tumor-promoting mechanisms of TLR9 are primarily mediated by its direct epithelial cell regulation, other mechanisms, for instance those impacting immune cell function, might also operate. Therefore, future reciprocal bone marrow chimera studies in both gp130F/F and H felis infection models will play a pivotal role in elucidating the relative contribution of TLR9-expressing bone marrow-derived hematopoietic (ie, immune) cells to gastric disease pathogenesis. We also note that our findings pave the way for future studies to investigate the role of the microbiome in triggering TLR9-induced gastric inflammation-associated tumorigenesis, for instance by comparing the extent of gastric tumorigenesis in germ-free gp130F/F versus gp130F/F:Thr9−/− mice, and/or specific pathogen-free gp130F/F versus gp130F/F:Thr9−/− mice treated with broad-spectrum antibiotics to eliminate gastric micobes.

**Methods**

**Human Biopsies**

Snap-frozen and formalin-fixed gastric tissue biopsies were collected from GC or GC-free patients enrolled at Monash Medical Centre (Melbourne, Australia) and Xinhua Hospital (Shanghai, China) undergoing surgical resection or upper gastrointestinal endoscopy (Table 1). Patients with a history of taking nonsteroidal anti-inflammatory drugs, proton pump inhibitors, or antibiotics were excluded. Histopathologic assessment and H pylori status were determined as before. Full and informed patient consent was obtained, and biopsy collections were approved by the Monash Health Human Research Ethics Committee and Xinhua Hospital Ethics Committee.

**Mouse Strains**

The gp130F/F and Thr9−/− mice (the latter donated by S. Summers, Monash University, Australia) have been described previously and were used to generate gp130F/F: Thr9−/− mice. All mice were on a mixed 129Sv×C57BL/6 background, and where possible equal numbers of male and female mice were used. Genetically matched and age-matched littersmates, including WT controls, were included in all experiments. Mice were housed under specific pathogen-free conditions on a 12-hour light/dark cycle. All animal experiments were approved by the Monash University Monash Medical Centre “B” Animal Ethics Committee.

**H felis Infection Model**

*H felis* (strain CS1) was cultured on horse blood agar (Oxoid, Nepean, Canada) and then harvested and cultured in brain heart infusion broth (Oxoid) to yield *H felis* suspensions for mouse inoculation. WT and *Thr9−/−* male and female mice aged 4–6 weeks were randomly administered with a single 100 μL aliquot of either control brain heart infusion broth or *2 × 107* *H felis* bacteria by oral gavage and then culled after 4 months.
**TLR9 Initiates Gastric Tumorigenesis**

**RNA Isolation and Gene Expression Analyses**

Total RNA was isolated from snap-frozen human and mouse gastric tissues and cultured human GC cell lines using TRI Reagent Solution (Sigma-Aldrich, St Louis, MO), followed by on-column rNeasy Mini Kit RNA clean-up and dNase treatment (Qiagen, Hilden, Germany). RNA was transcribed using the Transcript High Fidelity cDNA Synthesis Kit (Roche, Basel, Switzerland). qPCR was performed using the 7900HT Fast RT-PCR System (Applied Biosystems, Waltham, MA), and data were acquired and analyzed as before.\(^{58}\) Total RNA and qPCR analyses were performed on laser microdissected mouse gastric tissues as described before.\(^{58}\) Human (h) TLR9 and mouse (m) Tlr9 gene primer sequences are as follows, and for other genes primer sequences are available on request or have been previously published.\(^{8,11,31,32,57,58}\)

**Protein Expression Analysis**

Immunoblots were performed with antibodies against TLR9 (1:500 dilution) (Abcam), pSer\(^{536}\)-p65 NF-κB, pThr\(^{202}/\)pTyr\(^{204}\)-ERK1/2, pSer\(^{473}\)-Akt, pTyr\(^{705}\)-STAT3, total STAT3, total p65 NF-κB, total ERK1/2, total Akt (each at 1:1000 dilution) (Cell Signaling Technology and Actin (1:1000 dilution) (Sigma-Aldrich). Membranes were analyzed using the Odyssey Clx Imaging System (Li-Cor, Lincoln, NE), and protein expression was quantified as before.\(^{5,11}\) An ELISA kit to detect tumor necrosis factor α (BD Biosciences) in gastric tissue lysates was used according to manufacturer’s instructions.

**Cell Proliferation and Viability Assays**

AGS, NUGC4, MKN28, and gp130\(^{+/+}\) primary gastric epithelial cells (2 × 10\(^4\)) were seeded in triplicate wells in 96-well plates. After 24 hours of serum starvation, cells were treated with either ODN 2006 CpG oligonucleotide (Class B) or ODN 2006 control oligonucleotide (Invivogen, San Diego, CA) for 24 hours (proliferation) or 48 hours (viability). Where indicated, cells were also pretreated for 30 minutes with specific inhibitors against the ERK MAPK (U0126; 0.5 μmol/L; Cell Signaling Technology) and NF-κB (TPCA-1; 10 μmol/L; Selleck Chemicals, Houston, TX) pathways before stimulation with CpG or control oligonucleotides (both at 2 μmol/L). Cell proliferation was assessed with the ClickIT EdU Microplate Assay (Molecular Probes, Eugene, OR) and cell viability by using the MTT assay.\(^{5,11}\)

**Human Gastric Cancer Patient Datasets**

Gene expression data and clinical information from TCGA 18 intestinal-type GC cases with paired tumor and adjacent non-tumor tissue (Table 1), as well as 57 intestinal-type GC cases classified into H pylori-negative or -positive (Table 3), were obtained from TCGA data portal (https://portal.gdc.cancer.gov/projects/TCGA-STAD). We used

**Histology, Immunohistochemistry, and Immunofluorescence**

Formalin-fixed and paraffin-embedded mouse gastric tissue sections were stained with hematoxylin-eosin for histologic assessment. The extent of inflammation was blindly scored 0 (none), 1 (mild), 2 (moderate), and 3 (severe) independently by 2 authors, and the average was determined. Apoptosis was assessed by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay (Millipore, Burlington, MA), as well as immunohistochemistry with an anti-cleaved Caspase-3 antibody (1:100 dilution) (Cell Signaling Technology, Danvers, MA). Immunohistochemistry was also performed to evaluate cell proliferation with an antibody against PCNA (1:5000 dilution) (Cell Signaling Technology, Danvers, MA). Immunohistochemistry and proliferative index were determined using digital images of photo-micrographs (40 × magnification) viewed using Image software (National Institutes of Health, Bethesda, MD),\(^{56}\) and positive-staining cells were counted manually (n = 20 fields/section) and in a blinded manner. Immunofluorescence was performed with antibodies against TLR9 (AbCam, Cambridge, UK) at 1:50 dilution followed by Alexa Fluor 488 anti-rabbit secondary (Invitrogen, Waltham, MA) at 1:1000 and conjugated E-cadherin Alexa Fluor 488 (Cell Signaling Technology) at 1:100 dilution. Nuclear staining was achieved using 4',6-diamidino-2-phenylindole (DAPI). Sections that underwent the above staining protocol without primary antibodies acted as negative controls. Images were acquired using a Nikon C1 confocal microscope.

**Cell Culture**

Human GC cell lines AGS (American Type Culture Collection), MKN28 and NUGC4 (Japanese Collection of Research Bioresources Cell Bank) were grown in Gibco RPMI medium containing 10% fetal calf serum, 1% penicillin-streptomycin, and 1% L-glutamine (Thermo Fisher Scientific, Waltham, MA). Cell lines were characterized and authenticated via short tandem repeat profiling (PowerPlex HS16 System kit; Promega, Madison, WI) and were passaged for under 6 months after receipt in 2013. Cell lines were routinely tested for mycoplasma contamination using the MycoAlert PLUS Mycoplasma Detection Kit (Lonza, Basel, Switzerland). Primary gastric epithelial cells from gp130\(^{+/+}\) mice were generated and cultured using established protocols.\(^{57}\)

**FLA 5.6.0 DTD**

- JCMGH1031 proof - 30 June 2022 - 12:13 pm - cc CLR
Table 3. Clinicopathological Features and Demographics of The Cancer Genome Atlas (TCGA) Intestinal-type Gastric Cancer Patient Cohorts Used for TLR9 Expression Profiling Based on H. pylori Status

<table>
<thead>
<tr>
<th>Mean age</th>
<th>Hp-negative</th>
<th>Hp-positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years (range)</td>
<td>66.6 (44–90)</td>
<td>61.3 (45–78)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td>Male 35 (66)</td>
<td>3 (75)</td>
</tr>
<tr>
<td></td>
<td>Female 18 (34)</td>
<td>1 (25)</td>
</tr>
<tr>
<td>Tumor grade, n (%)</td>
<td>1</td>
<td>10 (18.9) 0</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>18 (34) 3 (75)</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>23 (43.3) 0</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>2 (3.8) 1 (25)</td>
</tr>
</tbody>
</table>

Hp, H. pylori.

reads/kilobase of exon model/million mapped reads to quantify TLR9 gene expression levels from RNA sequencing data generated from each GC patient.

The Gastric Cancer Project*08-- Singapore Patient Cohort (GSE15459) dataset (Table 1) was sourced for TLR9 gene expression profiling and overall survival analyses as described previously.10,23

Statistics

All statistical analyses were performed using GraphPad Prism V8.0.2 (San Diego, CA) software. Data normality was assessed using the Agostino and Pearson omnibus K2 normality test, and the appropriate tests to identify statistical significance (P < .05) between the means of 2 or multiple groups are presented in the relevant figure legends. All data in figures are expressed as the mean ± standard error of the mean from at least 3 technical replicates. The log-rank test was used to calculate the statistical significance of the difference in survival between 2 groups.

References


2204 42. Sokolova O, Naumann M. NF-κB signaling in innate immunity against Helicobacter pylori...


Received February 7, 2021. Accepted June 6, 2022.

Correspondence
Address correspondence to: Brendan J. Jenkins, Centre for Inmate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Monash University, 27-31 Wright Street, Clayton, Victoria 3168, Australia. e-mail: Brendan.Jenkins@hudson.org.au; fax: XXX.

CRediT Authorship Contributions
Ke Tang (Formal analysis: Supporting; Investigation: Lead; Methodology: Lead) Louise McLeod (Data curation: Equal) Thaleia Livis (Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting) Alison West (Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting) Ruby Dawson (Data curation: Equal) Liaa Yu (Investigation: Supporting; Methodology: Supporting) Jesse Balic (Investigation: Supporting; Methodology: Supporting) Michelle Chonwerawong (Investigation: Supporting; Methodology: Supporting) Georgie Wray-mccann (Investigation: Supporting; Methodology: Supporting) Hiroko Oshima (Data curation: Equal) Masanobu Oshima (Data curation: Equal) Virginie Deswaerte (Investigation: Supporting; Methodology: Supporting) Richard Ferrero (Funding acquisition: Supporting; Methodology: Supporting; Resources: Supporting; Supervision: Supporting; Writing – review & editing: Supporting) Brendan Jenkins (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Funding acquisition: Supporting; Lead; Project administration: Lead; Resources: Lead; Supervision: Lead; Validation: Lead; Writing – original draft: Lead)

Conflicts of interest
The authors disclose no conflicts.

Funding
Supported by research grants from the National Health and Medical Research Council (NHMRC) of Australia awarded to B.J. Jenkins (APP1139371) and R. L. Ferrero (APP1107930), as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. K. Tang was supported by Monash Graduate and Monash International Postgraduate Research Scholarships. R.L. Ferrero (APP1079904) and B.J. Jenkins (APP1154279) are supported by NHMRC Senior Medical Research Fellowships.